Device Trial Radar · NCT04219891
WaveLight® EX500 Excimer Laser System for the Correction of Myopia Using InnovEyes™ in Conjunction With InnovEyes™ Sightmap
Last checked: Nov 20, 2026Latest source record: Apr 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
272
Actual
Start
Mar 9, 2020
Primary completion
Nov 9, 2022
Study completion Nov 9, 2022
Sponsor
- Lead sponsor
- Alcon ResearchNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 7, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and effectiveness of the WaveLight EX500 excimer laser system for the correction of myopia with and without astigmatism using InnovEyes in conjunction with InnovEyes sightmap.
Conditions
- Myopia
Interventions
WaveLight EX500 excimer laser system with InnovEyes sightmapDevice
FDA approved stationary scanning-spot excimer laser system used during refractive surgery for the treatment of myopia, myopic astigmatism, hyperopia, hyperopic astigmatism, and mixed astigmatism. For this clinical study, the WaveLight EX500 software will be upgraded to include the InnovEyes treatment.
LASIKProcedure
Procedure that reshapes the front part of the eye (cornea) so that light traveling through it is properly focused on the back part of the eye (retina). The procedure will be performed using the WaveLight EX500 excimer laser system and data obtained from the InnovEyes sightmap.
InnovEyes sightmapDevice
Non-contact ophthalmic diagnostic device that captures images of the eye and collects ocular data preoperatively to generate a patient-specific ablation profile for refractive correction surgery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) of 20/40 or Better (in Eyes With Preoperative Best Corrected Distance Visual Acuity (BCDVA) of 20/20 or Better) at Refractive StabilityTime frame: Preoperative Visit (Day -30 to Day -1), Month 1, Month 3
- Percentage of Eyes With Manifest Refractive Spherical Equivalent (MRSE) Within +/- 0.50 Diopter (D) at Refractive StabilityTime frame: Month 1, Month 3
- Percentage of Eyes With MRSE Within +/- 1.00 D at Refractive StabilityTime frame: Month 1, Month 3
5 more outcomes with a free account
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Alcon Investigative Site
San Diego, California
Price Vision Group
Indianapolis, Indiana
Alcon Investigative Site
Chevy Chase, Maryland
6 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.